Lukotrap Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the effective management of allergic conditions. Levocetirizine is a potent, third-generation non-sedating antihistamine that selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene D4 receptor, reducing inflammation, bronchoconstriction, and mucus production in the airways. This dual action makes Lukotrap Tablet particularly beneficial in treating allergic rhinitis, asthma, and other hypersensitivity disorders by targeting both histamine-mediated and leukotriene-mediated pathways. The combination enhances symptom control, improves patient compliance, and may reduce the need for multiple medications. Lukotrap is generally well-tolerated, with a favorable safety profile; common adverse effects may include headache, fatigue, and gastrointestinal disturbances. It is contraindicated in patients with known hypersensitivity to either component. Use in pregnancy and lactation should be under medical supervision. Lukotrap Tablet should be used as directed by a healthcare professional, with dosage adjustments based on clinical response and patient-specific factors.